The FDA announced on Dec. 16, 2025, that Alembic Pharmaceuticals Limited is recalling Fesoterodine Fumarate Extended-release Tablets, 8 mg, due to failed impurity specifications. The agency stated the recall is voluntary and ongoing.
How to tell if you have it
- Brand: Alembic Pharmaceuticals
- Product: Fesoterodine Fumarate, Extended-release Tablets, 8 mg, 30 Tablets
- NDC: 62332-176-30
- Lot#: 2405003360
- Exp Date: Jan 31, 2026
The hazard
The recall is due to levels of 'Diester Impurity' exceeding the specification limit. The FDA's FAERS database contains 386 adverse-event reports naming this product, with 347 marked serious and 33 listing a death.
Context
GovInfoNow's records show Alembic Pharmaceuticals Limited has 6 other recalls on record since 2020-06-10. Other recent recalls of similar products include Alembic Fesoterodine Tablets Recall (2025-10-10), Alembic Doxepin Capsules Recall (2025-07-25), and Alembic Celecoxib Capsules 200mg Recall (2025-05-09). Other recent recalls of similar products include Zydus Mirabegron 25mg Tablets Recall (2026-08-05), Unichem Bisoprolol/Hydrochlorothiazide Tablets Recall (2026-01-21), and Sun Pharmaceutical Fexofenadine 180mg Tablets Recall (2026-06-01).